HOME >> MEDICINE >> NEWS
Canadian neurologist wins highest award as American Stroke Association honors five

NEW ORLEANS, Feb. 2 One of North America's foremost neurologists and stroke researchers, Vladimir Hachinski, M.D., D.Sc., professor of neurology at the University of Western Ontario, London, Ont., Canada, is the recipient of the American Stroke Association's highest honor the Thomas Willis Award for 2005.

Hachinski will receive the award and deliver the prestigious Willis Lecture today at the American Stroke Association's International Stroke Conference 2005 here in New Orleans.

Named for pioneer physician Thomas Willis (1621-1675), the award recognizes a senior investigator who has made major contributions to the understanding of stroke over a sustained period. Willis is credited with providing the first detailed descriptions of the brain stem, cerebellum and ventricles along with extensive hypotheses as to their functions.

In addition, John R. Marler, M.D. will receive the William M. Feinberg Award for Excellence in Clinical Stroke and Hermes A. Kontos, M.D., Ph.D., wins the Distinguished Scientist Award. Research awards will go to Hong Li, M.D., who is receiving the Mordecai Y.T. Globus New Investigator Award in Stroke and Shelagh Coutts, M.D., who wins the Robert G. Siekert New Investigator Award in Stroke.

An internationally recognized stroke investigator and innovator, Hachinski is the current editor-in-chief of Stroke: Journal of the American Heart Association and a past chair of the stroke conference program committee. He is past Richard and Beryl Ivey Chair of the Department of Clinical Neurological Sciences at the University of Western Ontario.

Hachinski pioneered the development of acute stroke units providing specialized patient care; discovered the key role of the central lobe in the cardiac complications of stroke and developed the "ischemic score" that bears his name. In addition, he was the first recipient of Canada's Trillium Award for outstanding research achievement.

Marler will receive the association's se
'"/>

Contact: Carole Bullock
carole.bullock@heart.org
214-706-1279
American Heart Association
2-Feb-2005


Page: 1 2 3

Related medicine news :

1. U of T researchers describe Joe Canadian tongue
2. Canadian researchers important discovery in HIV research
3. Impact of 2002 Canadian forest fires felt 700 miles away in Baltimore, Maryland
4. Canadian researchers to develop smart drug to repair psychiatric disorders
5. McMaster named Canadian Research University of the Year
6. Safety of Canadian hospitals
7. Patient safety study provides first national estimate of adverse events in Canadian hospitals
8. Canadian doctors dont know costs of prescribed treatments
9. New Canadian study demonstrates clear survival benefit of treatment in trials and at large centres
10. Canadian discovery promises treatment for HIV dementia
11. Most Canadian hospitals below recommended standards

Post Your Comments:
(Date:5/23/2013)... THURSDAY, May 23 (HealthDay News) -- A modified ... help fight brain tumors, preliminary research suggests. ... investigational therapy, known as PVSRIPO, uses an engineered ... normal cells, but attacks cancer cells. The therapy ... most common and aggressive brain tumor, they said. ...
(Date:5/23/2013)... when a woman harried by hot flashes says she,s ... published online in Menopause , the journal of ... objective tests that what these women say about their ... showed that hot flashes were related to memory problems, ... there was a relationship between hot flashes and what ...
(Date:5/23/2013)... Williamsport, PA (PRWEB) May 23, 2013 ... Sitter® Teaching Site, offering a comprehensive babysitting training course ... nationally-recognized program was developed by Indianapolis pediatrician Dr. Patricia ... in the care of an adult sitter who didn’t ... a well-rounded youth development program with a medical basis ...
(Date:5/23/2013)... drug about to be tested in a clinical trial ... treatment for Alzheimer,s disease has failed to work with ... patients, according to results of a study by University ... of neuroscience affiliated with the Evelyn F. and William ... emphasized the importance of verifying promising research results before ...
(Date:5/23/2013)... 2013 The Rottenstein Law Group LLP, ... created the Tylenol Lawsuit Information Center at http://www.rotlaw.com/tylenol ... and those who are considering filing lawsuits. , ... cause severe liver damage, according to a 2009 report ... the “safety communication,” the FDA warned consumers against using ...
Breaking Medicine News(10 mins):Health News:Modified Polio Virus May Help Fight Brain Tumors, Study Suggests 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 3Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 3Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2
(Date:5/23/2013)... 23, 2013  Spring Bank Pharmaceuticals, Inc., a biopharmaceutical ... infections, today announced that it has initiated dosing in ... once daily, oral therapy for the treatment of HCV ... and is designed to assess both the safety and ... first-in-class drug for the treatment of chronic HCV infections ...
(Date:5/23/2013)... FREDERICK, Md. , May 23, 2013  BioElectronics ... safe consumer medical devices, comments on the FDA panel ... Public Advisory Panel Reclassification – Pulsed Shortwave Therapy Meeting ... Gaithersburg, MD , USA.  The focus of the ... instructed the panel to focus solely on the application ...
(Date:5/23/2013)... , May 23, 2013 Halozyme Therapeutics, ... the appointment of David A. Ramsay ... was most recently Vice President, Corporate Development at ... "With his established financial management experience ... by working in our commercial group for the ...
Breaking Medicine Technology:Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3BioElectronics and Pulsed Shortwave Therapy Make Progress 2Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2
Cached News: